Citations

Showing 10 of 108083 citations.

Pleomorphic Liposarcoma of the Parapharyngeal Space: A Rare Case Report
Gruber, Karson M., Vasudevan, Srivatsa Surya , Janus, Jeffrey R.

Mayo Clinic

Ear, Nose & Throat Journal | December 22, 2022 | Volume: 104 | Issue: 1_suppl | Pages: No page available

10.1177/01455613221148312 | PMID 36548710 Get It

Pleomorphic liposarcomas (PLS) are the rarest subtype of liposarcomas, representing only 5–10% of liposarcomas. Pleomorphic liposarcomas are extremely aggressive and have a poor prognosis. Here, we present the case of a 66-year-old female who presented with difficulty swallowing, talking, and hearing. An extensive investigation revealed the presence of an aggressively growing parapharyngeal space mass. The patient underwent a left parapharyngeal space exploration and left deep lobe parotidectomy by the cervicoparotid approach. Histopathological evaluation of the surgical specimen further confirms the presence of pleomorphic subtype of liposarcoma. The patient received adjuvant radiotherapy following the procedure. At 6 months postop, the patient is in good health and shows no evidence of recurrence. In addition to this treatment, we discuss the radiologic and histologic findings of this current case.
“Uncomplicated” Type B Aortic Dissection: It’s Complicated
Rajiah, Prabhakar , Rajiah, Prabhakar

Mayo Clinic

Radiology: Cardiothoracic Imaging | December 22, 2022 | Volume: 4 | Issue: 6 | Pages: No page available

10.1148/ryct.220278 | PMID 36601451 Get It

Moving toward standardization: physician reporting of sleep studies
Lastra, Alejandra C. , Ingram, David G. , Park, John , James, Elisabeth, Matthews, Camilla K., Canapari, Craig , Stahl, Stephanie , Mansukhani, Meghna, James, Elisabeth, Mansukhani, Meghna P.

Mayo Clinic

Journal of Clinical Sleep Medicine | December 22, 2022 | Volume: 19 | Issue: 3 | Pages: 595-603

10.5664/jcsm.10442 | PMID 36546360 Get It

APOE2 Exacerbates TDP‐43 Related Toxicity in the Absence of Alzheimer Pathology
Meneses, Axel , Li, Zonghua , O’Leary, Justin , Li, Fuyao , Nakamura, M. , Kurti, Aishe, Heckman, Michael G. , White, Launia J. , Xie, Manling , Chen, Yixing , Finch, NiCole A., Lim, Melina J., Delenclos, Marion , DeTure, Michael , Martin, Nicholas B. , Ikezu, Tadafumi C. , Blitterswijk, Marka van , Wu, Long‐Jun , McLean, Pamela J. , Rademakers, Rosa , Ross, Owen A. , Bu, Guojun , Zhao, Na , Meneses, Axel D , Li, Zonghua , O'Leary, Justin, Li, Fuyao , Chen, Kai , Murakami, Aya , Qiao, Wenhui , Heckman, Michael G , White, Launia, DeTure, Michael A, Linares, Cynthia , van Blitterswijk, Marka M, Ross, Owen A , Dickson, Dennis W , Zhao, Na , van Blitterswijk, Marka , Wu, Long-Jun , Bu, Guojun , Chen, Yixing , Xie, Manling , McLean, Pamela J , Koga, Shunsuke , Chen, Kai , Dickson, Dennis W.

Mayo Clinic

Annals of Neurology | December 22, 2022 | Volume: 93 | Issue: 4 | Pages: 830-843

10.1002/ana.26580 | PMID 36546684 Get It

ObjectiveRecent evidence supports a link between increased TDP‐43 burden and the presence of an APOE4 gene allele in Alzheimer's disease (AD); however, it is difficult to conclude the direct effect of APOE on TDP‐43 pathology due to the presence of mixed AD pathologies. The goal of this study is to address how APOE isoforms impact TDP‐43 pathology and related neurodegeneration in the absence of typical AD pathologies.MethodsWe overexpressed human TDP‐43 via viral transduction in humanized APOE2, APOE3, APOE4 mice, and murine Apoe‐knockout (Apoe‐KO) mice. Behavior tests were performed across ages. Animals were harvested at 11 months of age and TDP‐43 overexpression‐related neurodegeneration and gliosis were assessed. To further address the human relevance, we analyzed the association of APOE with TDP‐43 pathology in 160 postmortem brains from autopsy‐confirmed amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with motor neuron disease (FTLD‐MND) in the Mayo Clinic Brain Bank.ResultsWe found that TDP‐43 overexpression induced motor function deficits, neuronal loss, and gliosis in the motor cortex, especially in APOE2 mice, with much milder or absent effects in APOE3, APOE4, or Apoe‐KO mice. In the motor cortex of the ALS and FTLD‐MND postmortem human brains, we found that the APOE2 allele was associated with more severe TDP‐43‐positive dystrophic neurites.InterpretationOur data suggest a genotype‐specific effect of APOE on TDP‐43 proteinopathy and neurodegeneration in the absence of AD pathology, with the strongest association seen with APOE2. ANN NEUROL 2023;93:830–843
Imaging of pediatric hematopoietic stem cell transplant recipients: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper
Coblentz, Ailish , Kaste, Sue C. , Mhlanga, Joyce , Parisi, Marguerite T. , Thacker, Paul G. , Voss, Stephan D. , Siegel, Marilyn J. , Chan, Sherwin S , Mhlanga, Joyce , Thacker, Paul G , Voss, Stephan D , Bhatia, Aashim , Weidman, Elizabeth K.

Mayo Clinic

Pediatric Blood & Cancer | December 22, 2022 | Volume: 70 | Issue: S4 | Pages: No page available

10.1002/pbc.30013 | PMID 36546505 Get It

AbstractImaging in hematopoietic stem cell transplantation patients is not targeted at evaluating the transplant per se. Rather, imaging is largely confined to evaluating peri‐procedural and post‐procedural complications. Alternatively, imaging may be performed to establish a baseline study for comparison should the patient develop certain post‐procedural complications. This article looks to describe the various imaging modalities available with recommendations for which imaging study should be performed in specific complications. We also provide select imaging protocols for different indications and modalities for the purpose of establishing a set minimal standard for imaging in these complex patients.
Neurogenic orthostatic hypotension after treatment with sorafenib
Wippel, Catherine Wegner, Deshpande, Hari A. , Patwa, Huned, Peixoto, Aldo J. , Wegner Wippel, Catherine

Mayo Clinic

BMJ Case Reports | December 22, 2022 | Volume: 15 | Issue: 12 | Pages: e247140

10.1136/bcr-2021-247140 | PMID 36549761 Get It

A man in his 70s with a history of fatigue, abdominal pain, and a palpable abdominal mass was found to have a peritoneal desmoid tumour. One year after diagnosis, he was prescribed sorafenib to limit tumour growth. Two months later, he developed dyspnoea on exertion and lower extremity weakness and was reported to have supine hypertension and orthostatic hypotension. On formal autonomic testing, he was noted to have severely impaired sympathetic responses and marked orthostatic hypotension without appropriate chronotropic response. A decision to hold sorafenib was made, and treatment was started with graduated compression stockings, liberal fluid and sodium intake, and midodrine. The patient had a modest and gradual improvement in his symptoms. To our knowledge, this is the first reported case of orthostatic hypotension related to sorafenib or any vascular endothelial growth factor inhibitors.
Extensive upfront validation and testing are needed prior to the clinical implementation of AI‐based auto‐segmentation tools
Roper, Justin , Lin, Mu‐Han , Rong, Yi

Mayo Clinic

Journal of Applied Clinical Medical Physics | December 22, 2022 | Volume: 24 | Issue: 1 | Pages: No page available

10.1002/acm2.13873 | PMID 36545883 Get It

Patient and Physician Decisional Factors Regarding Hypercalcemia of Malignancy Treatment: A Novel Mixed-Methods Study
Bassatne, Aya , Piggott, Thomas , Rahme, Maya , Fuleihan, Ghada El‐Hajj , Murad, Mohammad H, El-Hajj Fuleihan, Ghada , Piggott, Thomas , Murad, M. Hassan , Drake, Matthew T.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 22, 2022 | Volume: 108 | Issue: 3 | Pages: 563-584

10.1210/clinem/dgac630 | PMID 36545699 Get It

AbstractBackgroundIntegrating shared decision making between patients and physicians and incorporating their values and preferences in the development of clinical practice guidelines (CPGs) is of critical importance to optimize CPG implementation and treatment adherence. This applies to many debilitating diseases, including hypercalcemia of malignancy (HCM).ObjectiveEvaluate patient and physician values, preferences, and attitudes to better inform CPGs to treat HCM in adults.MethodsWe followed a mixed-methods approach. We conducted a systematic review using 5 databases to identify studies reporting on patient and physician values, costs and resources, feasibility, acceptability, and equity regarding HCM treatment. We also gathered data from different countries on the cost of multiple treatment modalities. We collected data on outcome prioritization from the CPG Working Group. Similarly, we collected data from patients with HCM regarding outcome prioritization and administered a questionnaire to evaluate their attitudes and perceptions toward treatment as well as treatment acceptability and feasibility.ResultsIn the systematic review, we included 2 cross-sectional surveys conducted on the same population of physicians who agreed that treating HCM alleviates symptoms and improves quality of life; however, harms and benefits should be thoroughly considered when deciding on the duration of treatment. We also included 2 studies on cost showing that intravenous (IV) bisphosphonate is more cost-effective than a combination of IV bisphosphonate and calcitonin and administration of IV zoledronic acid at home is more cost-effective than other IV bisphosphonates. The cost of zoledronic acid, denosumab, and cinacalcet varied widely among countries and types (brand vs generic). Both the CPG Working Group and patients with HCM agreed that the most important outcomes when deciding on treatment were survival and resolution of HCM, but there was some variability in the ratings for other outcomes.ConclusionUsing mixed methods, CPG developers can obtain meaningful information regarding evidence to decision criteria. In the case of HCM CPGs, this approach has provided the required contextual information and supported the development of evidence-based recommendations.
A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults
Seisa, Mohamed O. , Nayfeh, Tarek , Firwana, Mohammed , Saadi, Samer , Mushannen, Ahmed, Shah, Sahrish, Rajjoub, Noora S., Farah, Magdoleen H. , Fuleihan, Ghada El‐Hajj , Hasan, Bashar , Shah, Sahrish H, Drake, Matthew T , Murad, M Hassan , El-Hajj Fuleihan, Ghada , Nayfeh, Tarek , Saadi, Samer , Farah, Magdoleen H , Firwana, Mohammed M , Hasan, Bashar , Prokop, Larry J. , Wang, Zhen , Drake, Matthew T. , Murad, M. Hassan

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 22, 2022 | Volume: 108 | Issue: 3 | Pages: 585-591

10.1210/clinem/dgac631 | PMID 36545700 Get It

AbstractContextHypercalcemia is a common complication of malignancy that is associated with high morbidity and mortality.ObjectiveTo support development of the Endocrine Society Clinical Practice Guideline for the treatment of hypercalcemia of malignancy in adults.MethodsWe searched multiple databases for studies that addressed 8 clinical questions prioritized by a guideline panel from the Endocrine Society. Quantitative and qualitative synthesis was performed. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess certainty of evidence.ResultsWe reviewed 1949 citations, from which we included 21 studies. The risk of bias for most of the included studies was moderate. A higher proportion of patients who received bisphosphonate achieved resolution of hypercalcemia when compared to placebo. The incidence rate of adverse events was significantly higher in the bisphosphonate group. Comparing denosumab to bisphosphonate, there was no significant difference in the rate of patients who achieved resolution of hypercalcemia. Two-thirds of patients with refractory/recurrent hypercalcemia of malignancy who received denosumab following bisphosphonate therapy achieved resolution of hypercalcemia. Addition of calcitonin to bisphosphonate therapy did not affect the resolution of hypercalcemia, time to normocalcemia, or hypocalcemia. Only indirect evidence was available to address questions on the management of hypercalcemia in tumors associated with high calcitriol levels, refractory/recurrent hypercalcemia of malignancy following the use of bisphosphonates, and the use of calcimimetics in the treatment of hypercalcemia associated with parathyroid carcinoma. The certainty of the evidence to address all 8 clinical questions was low to very low.ConclusionThe evidence summarized in this systematic review addresses the benefits and harms of treatments of hypercalcemia of malignancy. Additional information about patients’ values and preferences, and other important decisional and contextual factors is needed to facilitate the development of clinical recommendations.
Laboratory Preparedness for the Current Monkeypox Outbreak
Rodino, Kyle G. , Bearman, Gonzalo , Binnicker, Matthew J. , Isaacs, Stuart N. , Pinsky, Benjamin A. , Pinsky, Benjamin A , Babady, N. Esther , Weber, David J.

Mayo Clinic

Clinical Chemistry | December 22, 2022 | Volume: 69 | Issue: 2 | Pages: 118-124

10.1093/clinchem/hvac198 | PMID 36544358 Get It